Welcome to our dedicated page for Lineage Cell Therapeutics SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lineage Cell Therapeutics, Inc. filings document the disclosures of a clinical-stage biotechnology company developing allogeneic cell therapies and cell transplant product candidates. The company’s reports and current-event filings cover financial results, business updates, pipeline developments, research collaborations, clinical-program milestones, and manufacturing progress involving programs such as OpRegen, OPC1, and ReSonance.
Regulatory filings also describe Lineage’s capital structure and financing activity, including common share offerings under shelf registration and at-the-market arrangements. Proxy materials cover board matters, executive compensation, equity awards, shareholder voting items, and governance disclosures, while 8-K filings record material events tied to collaborations, grant-related developments, operating results, and other corporate updates.
Lineage Cell Therapeutics (LCTX): Broadwood Partners, Broadwood Capital, and Neal C. Bradsher filed an amended Schedule 13D reporting updated ownership after the Issuer sold 12,000,000 common shares to Janus Henderson Investors in a block transaction under its at-the-market program, as described in a Form 8-K on November 12, 2025.
Broadwood Partners and Broadwood Capital each beneficially own 57,455,729 shares, representing 23.0% of the class. Mr. Bradsher beneficially owns 57,848,357 shares, or 23.1%, including stock options and warrants; he has sole voting and dispositive power over 392,628 shares and shared power over 57,455,729. Baselines reflect 250,222,274 and 250,527,274 shares outstanding, each as of the date hereof, as adjusted for the relevant derivative securities. No share transactions by the reporting persons occurred in the past sixty days. Purchases were funded by working capital and, for Mr. Bradsher, personal funds and director compensation.
Lineage Cell Therapeutics (LCTX) completed a capital raise. On November 12, 2025, the company sold 12,000,000 common shares to Janus Henderson Investors at $1.75 per share in a block transaction under its at-the-market program. The transaction generated $21 million in gross proceeds before fees and expenses.
This direct sale to a single institutional investor provides new cash to the company while increasing the share count. The pricing and size were fixed in the block trade, rather than dribbled out, which can offer execution certainty under an ATM framework.
Lineage Cell Therapeutics reported Q3 2025 results. Total revenue was $3.68 million (collaboration revenue $3.54 million). Operating loss was $3.79 million as R&D of $3.27 million and G&A of $4.19 million outpaced revenue. A large non-cash expense from the change in fair value of warrant liability ($26.56 million) drove a GAAP net loss of $29.75 million for the quarter.
Cash, cash equivalents and marketable securities totaled $40.5 million at September 30, 2025, and management states this is sufficient for at least twelve months of planned operations. Deferred revenue declined to $16.23 million as performance obligations were recognized, and warrant liabilities rose to $45.17 million. During the quarter, the company raised $1.32 million via its ATM program. The pipeline advanced: OpRegen received FDA RMAT designation in 2024 and showed positive 36‑month data in June 2025; the OPC1 DOSED study dosed its first chronic SCI participant with no significant safety events through 60 days; and a WDI collaboration will fund up to $12 million in ReSonance preclinical work. Common shares outstanding were 230,327,537 as of October 31, 2025.
Lineage Cell Therapeutics (LCTX) furnished an 8-K under Item 2.02 announcing financial results via a press release for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The company stated this information is being furnished, not filed, under the Exchange Act and will not be incorporated by reference except as expressly set forth by specific reference.
Jorey Chernett filed a Schedule 13G reporting beneficial ownership of Lineage Cell Therapeutics, Inc. common stock. The filer reports owning 11,445,003 shares, representing 5.01% of the class, and states sole voting and dispositive power over those shares. The filing includes an alternate line reporting 11,455,003 shares for sole voting and dispositive power, creating an inconsistency in the reported share counts. The registrant's principal office is listed in Carlsbad, California.
The filer certifies the shares were not acquired to change or influence control of the issuer and signed the filing on 09/25/2025.
Lineage Cell Therapeutics (LCTX) reported an insider notice to sell common shares under Rule 144. An earlier sale by Don M. Bailey on 09/10/2025 disposed of 80,000 shares for gross proceeds of $97,472. The current notice proposes the sale of 60,000 shares (approximate aggregate market value $96,024) to be executed on 09/24/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The 60,000 shares were acquired the same day by stock option exercise and paid in cash. The filing states the seller does not possess undisclosed material adverse information about the issuer.
Lineage Cell Therapeutics (LCTX) notice records a proposed sale of 80,000 common shares under Rule 144, with an aggregate market value of $97,472. The shares are listed on the NYSE and were acquired and are proposed to be sold on 09/10/2025 following a stock option exercise paid in cash. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the transaction and shows 228,356,290 shares outstanding, with no other sales by the filer in the past three months reported. The filer certifies no undisclosed material adverse information regarding the issuer.
Lineage Cell Therapeutics disclosed a new multi-year research collaboration with William Demant Invest 2 Aps (WDI) to advance its auditory neuronal cell transplant program, ReSonance (ANPI), aimed at treating hearing loss. WDI has agreed to fund up to $12 million in research collaboration costs over an approximate three-year term.
The collaboration focuses on completing preclinical work so the program may be ready to progress to human clinical trials under future clinical agreements to be negotiated in good faith. Each party keeps ownership of its existing intellectual property, while Project Results will generally be jointly owned, with specific provisions allowing one party to buy out the other’s interest if it decides not to continue into clinical development.
Lineage Cell Therapeutics, Inc. is registering an additional 19,500,000 common shares for issuance under its 2021 Equity Incentive Plan, following shareholder approval of a plan amendment on June 26, 2025. With this filing, the total common shares available for issuance under the 2021 Plan will not exceed 54,000,000 shares plus any Prior Plan Returning Shares that may become available over time. The plan covers stock options and restricted stock unit awards for employees, consultants, and non-employee directors, and this registration facilitates future equity-based compensation grants.
Lineage Cell Therapeutics reported stronger collaboration revenue and continued clinical progress while remaining a development-stage biotech with ongoing operating losses. Total revenues for the six months ended June 30, 2025 were $4.27 million, up from $2.85 million a year earlier, driven primarily by recognized collaboration upfront license fees. Cash and marketable securities totaled approximately $42.3 million at June 30, 2025 and management states these resources, together with available ATM capacity, are expected to fund planned operations for at least twelve months.
Operating results reflect continued R&D and G&A spending and a non-cash $14.84 million impairment of an acquired intangible asset, producing a net loss attributable to Lineage of $34.6 million for the six months. Balance sheet highlights include total assets of $90.8 million, warrant liabilities of $18.8 million (up from $6.2 million), and shareholders' equity of $47.1 million. Clinically, OpRegen showed sustained 36-month visual acuity gains in a subgroup (mean +9.0 ETDRS letters, n=5), OpRegen retains RMAT designation, and the OPC1 DOSED study has been initiated with the first chronic SCI patient treated.